NCT01034553 - Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions

Refractory Multiple Myeloma

Interventions

DRUG

Aurora A kinase inhibitor MLN8237

Given orally

DRUG

bortezomib

Given IV

Trial Locations (6)

Ohio State University, Columbus

Mayo Clinic, Rochester

Washington University School of Medicine, St Louis

Mayo Clinic in Arizona, Scottsdale

University of California, San Francisco, San Francisco

Dana-Farber Cancer Institute, Boston